FDA breakthrough device designation stimulates increased interest in Sinaptica - BioWorld Online

• BioWorld
• BioWorld MedTech
• BioWorld Asia
• BioWorld Science
• Data Snapshots
  • BioWorld
  • BioWorld MedTech
• Special reports
  • Aging
  • Artificial intelligence
  • Coronavirus
  • IVDs connected the rise
  • Top Biopharma Trends of 2021
  • Top Med-tech Trends of 2021
  • Premium reports
    • BioWorld Financings Reports
    • Disease Incidence & Prevalence Summaries

• Sign In
• Sign Out
• My Account

Subscribe

X

Subscribe to BioWorld™ quality services

See subscription options

Sinaptica Therapeutics Inc. received a U.S. FDA breakthrough instrumentality designation for its electromagnetic therapy for Alzheimer’s disease. Sinaptistim-AD combines neurostimulation, encephalon question monitoring and artificial quality (AI) to code the cognitive and functional diminution successful patients with the neurological disorder.

BioWorld MedTech Regulatory U.S.